Biology of breast cancer in young women.

Azim HA, Partridge AH. · 2014

Read Biology of breast cancer in young women. by Azim HA, Partridge AH. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4303229.txt.

Introduction

Hatem A Azim and Ann H Partridge review breast cancer that strikes women at a young age. Their review appeared in Breast Cancer Research in 2014. Such cases are uncommon in rich countries, yet they tend to run a harsher course than the same disease in older women, with worse outcomes.

Young patients' tumors differ in hormone receptors, HER2 status, and growth markers, and inherited risk genes are more common among them. The breast tissue itself differs at young ages, and pregnancy and breastfeeding leave changes that may shape later tumors. Treatment still follows the same plans as for older women, and the authors argue the biology deserves study of its own to sharpen prognosis and care.

Catalog record

CREATORAzim HA, Partridge AH.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4303229

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Biology of breast cancer in young women By Hatem A Azim, Ann H Partridge Published in: Breast Cancer Research : BCR DOI: 10.1186/s13058-014-0427-5 ABSTRACT Breast cancer arising at a young age is relatively uncommon, particularly in the developed world. Several studies have demonstrated that younger patients often experience a more aggressive disease course and have poorer outcome compared to older women. Expression of key biomarkers, including endocrine receptors, HER2 and proliferation markers, appears to be different in younger patients and young women are more likely to harbor a genetic predisposition. Despite these differences, little research to date has focused on the biology of these tumors to refine prognosis, and potentially direct treatment strategies, which remain similar to those offered to older patients. Accumulating evidence suggests the differences in breast stroma in younger patients and changes that occur with pregnancy and breastfeeding likely contribute to the different biology of these tumors. Reproductive behaviors appear to impact the biology of tumors developing later in life. In addition, tumors arising during or shortly following pregnancy appear to exhibit unique biological features. In this review, we discuss our emerging understanding of the biology of breast cancer arising at a young age at both the pathologic and the genomic level. We elucidate the potential role of genomic signatures, the impact of pregnancy and breastfeeding on breast cancer biology, and how even current knowledge might advance the clinical management of young breast cancer patients. Electronic supplementary material The online version of this article (doi:10.1186/s13058-014-0427-5) contains supplementary material, which is available to authorized users. INTRODUCTION Breast cancer is predominantly a disease of aging, with only 5 to 7% of patients diagnosed below the age of 40 years in the developed world [1]. In less developed regions where population-based screening is not routine and populations are much younger on average, such as in Africa and the Middle East, a higher proportion of patients are diagnosed below the age of 40, reaching as high as 20% [2],[3]. Whether there are underlying genetic differences or environmental factors that would render women in Africa and the Middle East more prone to develop the disease at a young age is the subject of ongoing research [4]. Nevertheless, young age at diagnosis of breast cancer has emerged world-wide as an independent factor associated with higher risk of relapse and death in several large studies, even when more aggressive therapies are administered [5]–[9] (Table 1). Expression of key biomarkers, including endocrine receptors, HER2 and proliferation markers, appears to be different in younger patients. Recent studies have attempted to control for tumor molecular subtypes, recognizing that more aggressive subtypes are more common in younger women. Two studies suggested particularly worse outcomes in young patients compared to older women with luminal-B tumors [7],[9]. It was hypothesized that younger patients were not offered standard hormonal therapy until a decade ago, and compliance to hormonal therapy is lower in young patients [10]. However, a study of women who were untreated with systemic adjuvant therapy also demonstrated poorer outcomes of young luminal-B patients [9]. These collective findings suggest that tumors arising in younger patients may be more aggressive due to biological differences. In this review we discuss the biological features of breast cancer arising in young women, and the emerging relationship with reproductive behaviors, including pregnancy and breastfeeding, and their potential clinical implications.Table 1 Recent large studies investigating the impact of age on breast cancer prognosis Young age, years (n)Control age, years (n)Outcome definitionImpact of young age on outcomeaFactors controlled in multivariate modelHazard ratio95% CIGnerlich et al. 2009 [5]<40 (15,548)≥40 (227,464)BC-specific survival1.391.34-1.45T, N, grade, race, marital status, ER, PgR, local therapyFredholm et al. 2009 [6]<35 (378)50-69 (13,486)BC-specific survival1.761.36-2.28T, N, grade, ER, multifocality, local and systemic therapyCancello et al. 2010 [7]<35 (315)35-50 (2,650)BC-related event1.71.33-2.18T, N, grade, histology, ER, HER2, PgR, ki67 vascular invasionHan et al. 2010 [8]<35 (1,443)40-50 (6,354)Overall survival30-34 years: 1.43 26–29 years: 1.971.18-1.74 1.48-2.62T, N, ER, systemic therapyAzim et al. 2012 [9]≤40 (339)>40 (2,562)Relapse-free survival1.341.10-1.63T, N, grade, BC molecular subtype, systemic therapyaIn multivariate models. BC, breast cancer; CI, confidence interval; ER, estrogen receptor; n, number; N, nodal involvement; PgR, progesterone receptor; T, tumor size. PATHOLOGICAL FEATURES OF TUMORS ARISING IN YOUNG WOMEN Recently, results of the largest prospective observation study evaluating the pathological features and outcome of women who were aged <40 years at diagnosis were reported [11]. This UK-based study included 2,956 patients diagnosed with breast cancer between 2000 and 2008. The median age at diagnosis was 36 years, and the majority had ductal histology (86.5%), and grade III (58.9%) tumors. Node-positive disease and multifocality were observed in 50.2% and 27%, respectively. One third of tumors were estrogen receptor (ER)-negative while one quarter were HER2-positive. Very similar results were observed among the first 399 patients evaluated in the Young Women’s Breast Cancer Study, which started in 2006 enrolling women aged 40 years or younger at diagnosis [12]. This study further demonstrated high rates of lymphovascular invasion and lymphocytic infiltration, in 34% and 24% of patients, respectively. Several other retrospective studies have evaluated differences in pathological features according to age [5],[13]–[15]. Gnerlich and colleagues [5] conducted the largest analysis including more than 200,000 patients of whom nearly 15,000 were aged <40 years at breast cancer diagnosis from a Surveillance, Epidemiology, and End Results database. Young patients were more commonly diagnosed with larger tumors (P < 0.0001), nodal involvement (P < 0.0001), poorly differentiated tumors (P < 0.0001), and endocrine receptor-negative tumors (P < 0.0001). A population-based study from the California Cancer Registry, which included 5,605 patients aged <40 years at diagnosis, further showed higher expression of HER2 in the younger population [15]. Several other hospital-based studies confirmed the same findings [13],[14], underscoring that tumors diagnosed in younger patients have more aggressive pathological features. PATTERN OF BREAST CANCER SUBTYPES ACCORDING TO AGE In recent years, breast cancer has been increasingly recognized as a heterogeneous disease with at least four subtypes: luminal-A, luminal-B, basal-like and HER2-enriched subtypes [16]. Figure 1 summarizes the two studies that have addressed the pattern of breast cancer molecular subtypes according to age using gene expression profiling. In the largest published study to date, Azim and colleagues [9] evaluated tumors of 3,522 patients, of whom 451 were aged ≤40 years at the time of breast cancer diagnosis. Young patients had a significantly higher proportion of basal-like tumors (34.3%) compared to 27.7%, 20.8% and 17.9% in patients aged 41 to 52, 53 to 64 and ≥65 years, respectively (P < 0.0001). A higher proportion of HER2-enriched tumors was also observed in young patients. On the other hand, young women were less likely to have luminal-A tumors (17.2%) compared to 30.7%, 35.1% and 35.4% in the other age groups (P < 0.0001).Figure 1Breast cancer subtypes. Subtypes determined by gene expression profiling. Other studies have addressed the question using immunohistochemical surrogates with variable definitions [7],[12],[17],[18] (Figure 2). This has resulted in different distributions of subtypes observed in the different studies. Of note, these studies were also hospital-based with potential for selection bias. The California Cancer Registry examined the differences in breast cancer subtypes according to age (<40, 40 to 49 and ≥50 years) but only based on the expression of ER and HER2 [15]. In line with other studies,

Read the complete text